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Abstract: The aging process includes impairment in mitochondrial function, a reduction in anti-oxidant
activity, and an increase in oxidative stress, marked by an increase in reactive oxygen species (ROS)
production. Oxidative damage to macromolecules including DNA and electron transport proteins
likely increases ROS production resulting in further damage. This oxidative theory of cell aging
is supported by the fact that diseases associated with the aging process are marked by increased
oxidative stress. Coenzyme Q10 (CoQ10) levels fall with aging in the human but this is not seen in all
species or all tissues. It is unknown whether lower CoQ10 levels have a part to play in aging and
disease or whether it is an inconsequential cellular response to aging. Despite the current lay public
interest in supplementing with CoQ10, there is currently not enough evidence to recommend CoQ10
supplementation as an anti-aging anti-oxidant therapy.
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1. Introduction
CoQ10 was first described in 1955, named ubiquitous quinone, a small lipophilic molecule located
widely in cell membranes [1], and in 1957 its function as an electron carrier in the mitochondrial electron
transport chain was reported [2]. The role in human disease was unknown for 20 years until in 1986
a benefit of CoQ10 treatment was reported in Kearns–Sayre syndrome [3]. Initially, therapeutic use of
CoQ10 was focused on the oxidative phosphorylation (OXPHOS) defects in which there is documented
CoQ10 deficiency [4] and in the group of CoQ10 synthesis disorders [5]. These conditions provided
evidence for efficacy and safety of treatment with CoQ10 [6]. Subsequent larger-scale trials in Parkinson
disease [7] and other neurodegenerative diseases have shown safety but no convincing benefit.
In the last decade, CoQ10 functions in membranes throughout the cell where antioxidant and
signaling roles predominate have been of increasing interest [8]. There is growing evidence that
oxidative stress is a major component of cellular senescence [9]. This multifactorial process involves
DNA injury [10], protein and lipid damage, and activation of signaling pathways associated with
aging [11]. Recently, the CoQ10 antioxidant effect has been shown to reduce markers for cardiovascular
disease (CVD) and inflammation, the main components of atherosclerotic vascular disease [12].
It is suggested that CoQ10 supplementation can improve the symptoms of mitochondrial diseases
and of aging because of an improvement in bioenergetics [12,13].
Our objective is to review, from a translational perspective, data regarding the association of
CoQ10 and aging. Are the aging process and mitochondrial progressive failure related and can CoQ10
supplementation decelerate aging?
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2. CoQ10
2.1. What Is It?
Coenzyme Q10, CoQ10 or ubiquinone (2,3 dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone)
is a small lipophilic structure, composed of a benzoquinone ring and an isoprenoid side-chain and it is
found universally in cell membranes. In humans, synthesis occurs utilizing a collection of enzymes
(complex Q) located in the mitochondrial matrix membrane [14]. The benzoquinone ring is derived
from 4-hydroxybenzoic acid, while 10 isoprenes are derived from mevalonic acid (from the cholesterol
synthesis pathway). The quinone ring is the functional group in the molecule, responsible for carrying
electrons to complex III. CoQ10 (ubiquinone) is reversely reduced to ubiquinol. The polyisoprenoid
tail is very lipophilic and localizes to hydrophobic membranes. The length of the isoprenyl chain is
variable between species with 10 isoprenes forming human CoQ10 whilst rodents predominantly have
CoQ9 [15].
2.2. Function
CoQ10 is widely distributed in all cell membranes and forms a critical component of the electron
transport chain (ETC) transporting electrons between complexes I/II and III [13]. In rat liver the largest
ubiquinone (CoQ9) concentration is found in the Golgi vesicles (2.62 µg/mg) followed by mitochondrial
matrix membrane and lysosomes (with levels of 1.86 in each structure) [16].
The major function of ubiquinone is in the mitochondrial ETC. CoQ10 accepts electrons from
different donors, including complex I (reduced nicotinamide adenine dinucleotide [NADH]-coenzyme
Q oxidoreductase), complex II (succinate dehydrogenase), the oxidation of fatty acids and
branched-chain amino acids via flavin-linked dehydrogenases and electron transfer factor Q
oxidoreductase (ETF-QO) to complex III (ubiquinone-cytochrome c oxidoreductase) [17,18]. CoQ10
cycles between its three chemical forms: completely oxidized (ubiquinone), a semi-oxidized
intermediate free radical (semiquinone) and a completely reduced form (ubiquinol) as shown in
Figure 1 [19,20]. By moving within the mitochondrial membrane, the proton-motive Q cycle allows
proton pumping at complex III helping to generate the proton motive force for adenosine triphosphate
(ATP) production.
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CoQ10 supplementation has been shown to have epigenetic effects in genes involved with
signaling, intermediary metabolism, transport, transcription control, disease mutation, phosphorylation,
and embryonal development indicating a role in modulation of gene expression [22,23].
In addition to its major function in the ETC, CoQ10 has an important anti-oxidant role stabilizing
the plasma membrane and other intracellular membranes protecting membrane phospholipids from
peroxidation [13]. Ubiquinone and semiquinone are also involved with recycling of other anti-oxidant
molecules, reducing α-tocopherol and ascorbate contributing to redox balance in the cell. Diminished
CoQ10 levels in aging likely contribute to membrane peroxidation injury. There is evidence that
part of its anti-oxidant effect occurs by enhancing the enzymatic activity of the antioxidant proteins
superoxide dismutase and glutathione peroxidase [24]. Recent publications associate ubiquinol with
protection of plasma low density lipoproteins (LDL) from oxidation, an important anti-atherogenic
effect [25]. The pro-oxidant role of CoQ10 is a signaling function involved in gene expression but the
mechanism of this function is not fully understood [26,27]. Other functions include modulation of
the permeability transition pore, thus playing a role in apoptosis [28]. CoQ10′s main functions are
summarized in Figure 2.
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Figure 2. The Multiple Roles of Ubiquinone in the Cell.
Chronic inflammation is a frequent aging-related problem. CoQ10, by reduction of free radicals,
reduces the activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) cells
and consequently reduces the release of pro-inflammatory cytokines mainly tumor necrosis factor
alpha (TNF-α) and interleukin 6 (IL-6) [29]. Aging-related reduced CoQ10 levels may contribute to
inflammation and there is accumulating evidence of secondary anti-inflammatory effects of CoQ10
supplementation. A recent meta-analysis provided evidence that CoQ10 supplementation significantly
reduced the inflammatory markers CRP (C-reactive protein), IL-6 and TNF-α [30]. Another recent
publication reported that patients with metabolic diseases (obesity, type 2 diabetes, metabolic syndrome,
cardiovascular disease, and nonalcoholic fatty liver disease) had a significant decrease in TNF-α
plasma levels with CoQ10 supplementation but not CRP or IL-6 [31]. CoQ10 was found to have
an anti-inflammatory function via epigenetic effects on expression of genes related to NFkappaB1
(NFk-B1) [32]. CoQ10 has a hepatoprotective and neuroprotective effect in a rat model of non-alcoholic
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steatohepatitis [33] apparently through an adenosine 5′ monophosphate-activated protein kinase
(AMPK) activation mechanism and in humans a randomized trial showed that supplementation of
CoQ10 improved biomarkers for inflammation in nonalcoholic fatty liver disease (NAFLD) [34]. CoQ10
supplementation in patients with antiphospholipid syndrome has been found to attenuate levels of
pro-inflammatory and thrombotic markers, with evidence of endothelial and mitochondrial function
improvement [35]. In Down syndrome patients, chronic neuro-inflammatory changes have been
proposed as a possible accelerator of Alzheimer disease [36]. These include high levels of interleukin
6 and tumor necrosis factor α along with decreased levels of CoQ10. A positive correlation between
CoQ10 and intelligence quotient levels was also reported [37]. CoQ10 treatment in Down syndrome
cells is associated with improved DNA repair mechanisms and DNA protection [38].
Cardiovascular disease is a common aging-related problem. There is a considerable body of
evidence supporting a role for CoQ10 in cardiovascular function including a correlation of low
endomyocardial levels with severity of heart failure and an improvement in cardiac contractility with
CoQ10 treatment [39]. Improvement in lipid profiles (a major contributor to cardiovascular disease)
has been reported with CoQ10 treatment [40].
CoQ10 has other important functions, participating in metabolic pathways as an electron receptor:
(1) CoQ10 is a co-factor for dihydro-orotate dehydrogenase, an enzyme involved in the de novo
pyrimidine biosynthesis [41]. (2) During the process of sulfide oxidation CoQ10 accepts electrons
from the enzyme sulfide-quinone reductase to convert sulfide into thiosulfate [42]. (3) The oxidation
from choline to glycine is catalyzed by choline dehydrogenase in the inner mitochondrial membrane,
and CoQ10 is proposed to be the electron acceptor for this reaction [43]. (4) Proline dehydrogenase
donates electrons from FAD and NAD+ to CoQ10 during process of synthesis of proline and
arginine [21,44].
2.3. Sources of CoQ10
2.3.1. Internal Biosynthesis
CoQ10 is the only lipid-soluble antioxidant synthetized by the human body [13]. The majority of
CoQ10 comes from the internal synthesis, from tyrosine or phenylalanine (benzoquinone ring) and
mevalonic acid (isoprenoid side-chain). Synthesis occurs in all tissues studied. In humans synthesis
occurs utilizing a collection of enzymes (complex Q) located in the mitochondrial matrix membrane
and in the endoplasmic reticulum The mevalonic acid pathway is responsible for cholesterol synthesis
with 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (the site of statin inhibition)
as the regulatory step. CoQ10 derived from dietary intake becomes more important with aging as
endogenous production decreases [13].
At least 14 genes are involved in CoQ10′s biosynthesis in yeast with 18 genes so far reported
in humans. Many are homologues of genes identified in c. cerevisiae. These synthetic proteins are
nuclear encoded and require mitochondrial targeting sequences for entry into the matrix or the inner
mitochondrial membrane [14]. There is assembly of many of the components into a ‘supercomplex’
termed Complex Q in the mammal. Mitochondrial synthesis is thought to occur in all cells containing
mitochondria but also in other organelles including the endoplasmic reticulum and peroxisomes [45].
Figure 3 summarizes the mammalian CoQ10 biosynthesis pathway.
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2.3.2. External Sources
CoQ10 is widely found in many animal protein sources (pork, lamb, beef, chicken, fish), vegetables
(spinach, pea, broccoli, cauliflower), fruits (orange, strawberry, apple) and cereals (rye, wheat) [13].
Heart, chicken leg, herring, and trout contain particularly high amounts of CoQ1 . Daily intake
between 3 and 5 mg is cons dered ad quate and whilst ext rnal supplementati reases plasma
leve s, suppl mentation w s ot thought to increase ti sue levels of CoQ10 in ti s ith normal
synthetic capacity [46], although evidence of treatment efficacy in a variety of human diseases does
suggest that tissue uptake can occur [13,47].
2.3.3. Absorption and Transport
CoQ10 absorption is slow and occurs in the small intestine; in its reduced form, ubiquinol is 3
to 4 times better absorbed than the oxidized form, ubiquinone [48]. The absorption of CoQ10 can be
increased if administered wit food intake, mainly with lipids because of it lipophilic structure [13,49].
After absorption by the enter cytes, CoQ10 pas es through lymphatic ve sels and r ache the plasma,
where it circulates bound to lipoproteins (LDL). Because of this, plasma measurements of CoQ10 should
be corrected for lipoproteins levels. Between 80 and 95% of plasma circulating CoQ10 is in the reduced
ubiquinol form. [48,50].
2.4. Tissue Levels and Distribution of CoQ10
Although the major CoQ10 plasma form is ubiquinol, laboratory measurements, in general, report
the CoQ10 total level [50]. Lymphocyte and platelet levels may give some insight into levels in less
accessible tissues such as heart, muscle, and brain [51]. The CoQ10 level varies in different tissues.
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Tissues with a higher metabolic rate and mitochondrial content (heart, kidney, liver, and muscle) have
high levels of CoQ10, for example the level is 8 µg/g in lung and 114 µg/g in heart [13]. Tissue levels
largely reflect the results of synthesis and degradation of CoQ10. Following intestinal absorption,
liver and lipoprotein concentrations increase, but without a change in the level in heart and kidney
noted in early studies [52]. However, there is some evidence that chronic administration can increase
tissue levels [53]. In a study where rats were chronically fed a large dose of 150 mg/kg/day of CoQ10
for 13 weeks, small but significant increases in both CoQ9 and CoQ10 were found in all tissues
measured [54]. No such data exist for young or aged human tissues; however, the accumulated
evidence of benefit of CoQ10 therapy in human disease states does suggest that tissue levels can be
increased by oral administration. The number, size, and structure of the mitochondria in each cell
determines the tissue level of CoQ10 with highest levels found in tissues with high energy demands
and a high mitochondrial content [13,48].
The gold standard for the diagnosis of CoQ10 deficiency is based on the measurement of muscle
level by high-performance liquid chromatography (HLPC) [55,56]. Plasma levels of CoQ10 range
between 0.40 and 1.91µmol/L (0.34–1.65µg/mL) in controls [57] but do not match tissue levels, reflecting
consumption much more than endogenous synthesis. The diagnosis of CoQ10 deficiency requires
tissue measurement [58]. There is evidence suggesting that the CoQ10 level in mononuclear cells can be
correlated to muscle measurements [45,56]. Plasma CoQ10 levels are increased in some physiological
conditions (cold adaptation and exercise) and in some diseases (paraneoplastic nodules, Alzheimer’s
disease, and prion disease). Levels are decreased in aging. [45].
2.5. Causes of Reduction
Conditions associated with CoQ10 deficiency can be divided into three main groups: (1) CoQ10
nutritional deficiency, including intake of CoQ10 itself and nutrients and vitamins necessary for its
synthesis (vitamin B6 is a cofactor in the pathway of CoQ10 biosynthesis); (2) CoQ10 synthesis genes
(COQ family genes: COQ1 and the Complex Q genes including the mammalian homolog of the yeast
Coq11 gene; the Complex I subunit NDUFA9), and acquired disorders impairing CoQ10 synthesis
(statin use) [59–61]; and (3) medical conditions associated with decreased levels of CoQ10 [45,46]. In this
last category, a variety of conditions have been reported with low CoQ10 including neurodegenerative
disorders Friedreich’s ataxia, Nieman–Pick type C disease, and Parkinson Disease. In other disorders
such as Alzheimer disease, diabetes, cancer, fibromyalgia, and cardiovascular diseases, elevations in
plasma CoQ10 levels may be a stress response. [45,46]. Defects in genes which may be associated with
reduced CoQ10 levels can be included in this group (APTX, ETFDH, BRAF).
Special attention should be given to the important observation that CoQ10 deficiency is potentially
reversible if the supplementation starts before the appearance of the symptoms, when brain and kidney
have not sustained permanent damage [46,62].
2.6. Supplementation
2.6.1. Dosing
A recent trend over the last few years has been to supplement adult patients with mitochondrial
diseases with high doses of oral CoQ10 or ubiquinol, up to 1200 mg/day or higher. For the pediatric
population, doses between 5 and 10 mg/kg/day of ubiquinol are recommended [63]. For a dose of
10 mg/kg/day, plasma levels range between 5 and 10 µg/mL 3–4 weeks after the beginning of the
supplementation [53,63,64]. As explained above, there are important differences in bioavailability of
the different formulations of CoQ10 used; ubiquinol (the reduced form) is 3 to 4 times better absorbed
than ubiquinone (oxidized form) [48]. Primary CoQ10 diseases tend to respond to supplementation but
may require very high doses. Also, some patients with secondary CoQ10 dysfunction were reported
to improve some symptoms with CoQ10 supplementation. Examples are cardiomyopathy in organic
acidurias (25 mg/kg/day with improvement in the cardiomyopathy) [65], glutaric acidemia type II
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(500 mg per day of CoQ10 along with riboflavin with improvement in strength, lactate, and creatine
kinase levels) [59], ataxia oculomotor apraxia type 1 (200–600 mg with reported improvement in
strength, ataxia, and cessation of seizures in one patient) [60], GLUT-1 deficiency (30 mg/kg/day with
improvement in the ataxia and nystagmus) [66].
Exogenous administration of CoQ10 reportedly does not raise tissue levels above normal in healthy
young individuals, except for two tissues (liver and spleen) [13]; however, this traditional view may be
wrong given the improvement in multi-organ symptoms in a variety of disorders with mitochondrial
dysfunction when treated with CoQ [67].
2.6.2. Safety and Adverse Events
Although the majority of studies have not shown convincing enough scientific evidence to support
treatment with CoQ10 in specific diseases, they do provide evidence that oral supplementation is
safe and well tolerated. One of the largest trials was a phase III randomized, placebo-controlled,
double-blind clinical trial at 67 North American sites by the Parkinson Study Group using doses of CoQ10
up to 2400 mg/day demonstrated the safety of this dose [7]. Evidence suggests that supplementation
does not inhibit endogenous production [13]. Previous studies had reported only mild side effects
such as gastrointestinal symptoms, mainly nausea, with CoQ10 supplementation [13,68].
3. Aging
3.1. Physiology of Mitochondrial Involvement in the Process of Aging
Human aging is a normal multifactorial process resulting from the interaction of genetic and
environmental factors. It is characterized by multi-organ system functional decline in association
with the risk of age-related diseases (dementia, neurodegenerative disorders, osteoporosis, arthritis,
diabetes, cardiovascular disease, age-related hearing loss, and cancer) [13,68–71].
A common hypothesis to explain some of the pathophysiology of age and degenerative diseases is
an oxidative imbalance between the production of reactive oxygen species (hydrogen peroxide: H2O2,
the oxygen-derived free radicals superoxide: O2•−, and hydroxyl radical: HO•), and antioxidant
mechanisms such as superoxide dismutase, catalase, glutathione peroxidase, ascorbic acid, tocopherol,
glutathione, and CoQ10, leading to a state of oxidative stress [72–80]. A number of animal models
support this theory with shortened survival in mice lacking superoxide dismutase 1 (SOD1) and a lethal
phenotype in mice lacking superoxide dismutase 2 (SOD2) [81,82].
As mitochondria are the main source of reactive oxygen species (ROS) production though OXPHOS
supercomplex activity in the cristae of the inner mitochondrial membrane (mainly at complex I and
III), this organelle is the major target of ROS damage. Mitochondrial DNA (mtDNA) is particularly
vulnerable with a high mutation rate and limited mtDNA repair mechanisms [69,74]. The continuous
production and accumulation of mitochondrial ROS is the basis for “the free radical theory of
aging” [70,71]. Although the accumulation of ROS has a major effect on DNA (strand breaks, oxidation
of bases, damage in sites coding for ETC proteins), other structures of the cell are also damaged: lipids,
membranes, proteins (leading to dysfunction of the ETC, inadequate ATP production, and further ROS
production) [72–75]. There is evidence that impaired mitochondrial machinery produces more oxidative
stress and more ROS production, resulting in a vicious cycle [76,83]. Electrons leaking from impaired
OXPHOS react with oxygen molecules to form the free radical superoxide [80]. There is also an effect on
mitochondrial dynamics with impairment of fission, contributing to mitochondrial enlargement, which
reduces recycling through mitophagy leading to a reduction in ATP generation [73]. Impairment of the
mitochondrial–lysosomal axis occurs with aging, with accumulation of lipofuscin inside lysosomes
with senescence. Lipofuscin accumulation is postulated to limit the ability of lysosomes to participate
in mitophagy [73].
Considerable evidence supports the relationship between ROS accumulation and mitochondrial
dysfunction leading to aging (the mitochondrial free radical theory of aging): ROS production increases
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in aged humans and animals [70,84], imbalance in the levels of pro and anti-oxidant substances
occurs [85] with high levels of oxidized and damaged macromolecules (proteins, lipids, and DNA) [86].
There seems to be a convincing relationship between high ROS levels and longevity in humans and
animals [87]; however, the exact role of ROS remains unclear as some animal models report a failure to
increase longevity with ROS reduction and others link high levels of ROS and longevity. It remains
unclear what the contribution of ROS generation is versus epigenetic factors modulating genes related
to the protection from effects of aging [77,88,89]. Evidence against the oxidative theory of aging comes
from some animal models where longevity is unaffected by increased ROS production. Some of these
studies are detailed below.
Growing evidence supports the idea that increased levels of ROS are associated with the specific
biochemical pathway that improves longevity, at least in some species [90]. C. elegans, a nematode
mutant model clk-1 (COQ7 equivalent gene in humans), has higher longevity associated with higher
ROS production. C. elegans with a point mutation in the gene isp-1, responsible for an iron-sulfur
mitochondrial complex, also demonstrate an increase in life span [91]. These observations point out
the multiple roles of ROS particularly as signaling molecules triggering protective pathways. Some
mouse models of defective CoQ synthesis are difficult to square with the oxidative theory of aging.
Mice with only one copy of the gene Mclk1 (equivalent of mammals COQ7 and C. elegans clk-1 model)
have higher production of ROS in the mitochondria (although a normal level of total ROS in the body),
a higher level of protection of the immune system (from some infections and also tumorigenesis) and
increased longevity [92]. Homozygous knockout of the Mclk1 gene is embryonic lethal but utilizing
a Tamoxifen dependent transgene mouse KO activated at 2 months of age a multisystemic disorder
(heart, kidneys, and skeletal muscles) with a decline in ubiquinol levels is produced. At 8 months
this “ubiquinol deficit” animal presented normal levels of some factors associated with oxidative
stress (catalase, F2-isoprostanes, DNA oxidative damage, SOD1, and SOD2). Diet supplementation
at 9 months with an analogue of the ubiquinol precursor 4-hydroxybenzoic acid rescued the clinical
phenotype [93]. Another mouse model heterozygous for the Sod2 gene (with decreased Mn-superoxide
dismutase activity) does show oxidative injury (increased tumor incidence and DNA damage) but
does not decrease longevity [94]. The concept that mitochondrial dysfunction may be a consequence of
aging factors rather than a cause is also supported by observations of sarcopenia in rat and human
muscles with other factors such as denervation playing a role [95].
Further studies are needed to understand the balance of ROS as an agent of oxidative injury and
its signaling epigenetic role modulating genes related to the protection of effects of aging. It may be
that after the saturation of the mechanisms of protection, the ROS-stress protective cascade can no
longer prevent oxidative damage [88].
It is not surprising that given the contradictory evidence for a central role for ROS in aging,
evidence supporting the utility of anti-oxidant therapies in aging (such as CoQ10) remains unclear.
3.2. CoQ10 and Aging, CoQ10 Deficiency in Advanced Age, Evidence for Beneficial Supplementation
Published results from various research groups about CoQ levels and lifespan are often at variance,
model dependent and do not support a similar pattern in all species [96–98].
3.2.1. C. elegans
Studies in the nematode C. elegans have produced unexpected results compared to mammals.
As discussed above, a nematode mutant model clk-1 (mammals COQ7 equivalent gene), with low
production of CoQ8, has an extension in longevity compared with the wild strain but requires dietary
Q supplementation [99]. This diet does trigger a Dauer long-lived larval anerobic state. Other studies
with CoQ gene knockouts confirm that deficiency in CoQ (less than 50%) also leads to an increase in
lifespan, and a possible explanation is that less ROS production occurs in the case of moderate CoQ
deficiency [100,101], but with more severe depletion of CoQ, longevity would be affected [100,102].
This finding was also confirmed in human cells, with two different studies from the same group
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reporting that fibroblasts with mutations on PDSS2 (homologue of yeast coq1) with less than 12 and
20% of CoQ10 of control cells had decreased synthesis of ATP without increase in the levels of ROS.
However, when the defect was of 30%, with partial defect in the synthesis of ATP the levels of ROS
were higher. The explanation proposed centered on the severity of the deficiency of coenzyme Q as
an oxphos modulator [103,104].
3.2.2. Rodent Models
A diet supplemented with Ubiquinol-10 in the senescence-accelerated mouse prone 1 (SAMP1)
reduced markers of oxidative stress (ratio of reduced and oxidized glutathione—GSH/GSSG),
decelerated the normal decline in expression of genes (Sirt1, Sirt3, and Pgc-1a, and Ppara), and their
respective proteins related to mitochondrial function during aging [105]. This treatment also increased
auditory brainstem response hearing loss. The proposed mechanism of CoQ10 benefit as an anti-oxidant
agent in this aging mouse is through cyclic adenosine monophosphate (cAMP). There is an enhancement
in sirtuin genes, and PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha)
with increased complex I and IV activity and reduce oxidative stress. Despite all these beneficial
effects, there was no significant change in the overall lifespans compared to the control animals [105].
These findings of increased cAMP, SIRT1 (sirtuin 1) expression, and PGC-1α in reducing parameters of
oxidative stress and increasing mitochondrial function were also confirmed in other experiments with
ubiquinol supplementation in senescence-accelerated mice, with added benefits in obesity, insulin
resistance, and metabolic syndrome, (hypothesized mechanism in Figure 4 [106]). PPARα (peroxisome
proliferator-activated receptors) signaling and lipid metabolism gene expression changes in liver of
C57BL6J mice was reported after one-week supplementation with ubiquinol (250 mg/kg BW/day) [23].
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Interestingly mice with a single copy of the Coq7 synthesis gene demonstrated increased
longevity [107]. However the mechanism is unclear and several studies report that dietary
supplementation with CoQ10 or ubiquinol in various rat models improves mechanisms involved with
mitochondrial biogenesis, including parameters of oxidative stress [105,108–111].
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3.2.3. Mammals and Tissue CoQ levels
In mammals there is a tendency to ubiquinone to be reduced with age, but this finding depends on
the tissue investigated and also the species [97]. Early studies suggested that tissue levels of ubiquinol
were endogenously produced with little change with dietary supplementation except in liver and
spleen; however, subsequent studies in rodents confirm that oral supplementation with CoQ10 does
increase tissue levels of both CoQ10 and CoQ9 in skeletal muscle, heart, and kidney [26], and when high
doses (200 mg/kg) are used for 2 months in rats, brain levels are increased and are neuroprotective [112].
In humans, there is also a lack of consistent data. One study did not find a relationship between
aging and CoQ10 plasma levels in elderly women [113]. Others report that plasma and tissue levels
change over time, with a peak in pancreas and adrenal by 1 year of age and in the brain, heart, and lung
by 20 years. After this peak, levels decrease over time [114]. A decrease in brain CoQ10 was confirmed
in other studies [115,116]. Only 50% of the myocardial CoQ10 endogenous production remains by the
age of 80 [114]. Serum total CoQ10 and ascorbic acid levels were decreased in centenarians compared
with 76-year-old controls. An elevation of the CoQ10 binding protein prosaposin was also noted
presumably in an attempt to compensate for low CoQ10 levels [117]. The authors conclude that CoQ10
supplementation could be beneficial for centenarians. However, it is not known if low tissue and
plasma CoQ10 levels contribute to or are a side effect of aging.
Reduction of CoQ10 with age is postulated to result from reduction in biosynthesis coupled
with an increase in degradation attributed to age-related modification in lipid membranes, which
alters quinone behavior [118]. This reduction of CoQ10 levels has a tissue/organ specificity with
reported high levels of CoQ10 in the brain mitochondria from old rats [26], and reduced level in the
muscle [98]. A recent paper showed age-related reduction in mitochondrial respiration parameters
and ATP production in epithelial cells, rescued with CoQ10 administration. Both cited that parameters
decrease as age increases, as seen in Figure 5, with the estimate of 10% reduction in mitochondrial
respiration every ten years [70].
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High CoQ10 concentration was reported to be associated with higher physical activity, lipid
peroxidation, and lower oxidized LDL levels in elderly people. The same publication describes higher
levels of plasma CoQ10 in elderly (more than 50 years old) people compared with young (less than
30 years) [119]. The same group confirmed lower lipid peroxidation and lower oxidized LDL in young
adults and also showed that CoQ10 is lower in obese elderly patients [120].
In another study, prolonged CoQ10 supplementation for 4 years in community-dwelling elderly
was associated not only with an improvement in health-related quality of life but more importantly
with a lower “more days out of hospital“ rate. In this study, subjects were co-supplemented with
selenium [121].
Although the association between CoQ10 and muscle power is not well established, one study
showed a positive relation between CoQ10/cholesterol levels and hand grip, and lower ubiquinol levels
in patients with less muscle strength. This study was undertaken to evaluate a possible relationship
between low levels of CoQ10 and ubiquinol in sarcopenia [122].
Despite the multiple reports on the effects of CoQ10 supplementation on aging-related oxidative
markers, reduction in biomarkers related to inflammation and in DNA repair mechanisms reports
there is a great need for more controlled studies in an older population to determine effectiveness of
CoQ10 as an anti-aging therapy [97] and also to determine the tissue CoQ10 levels in the human species
during senescence.
3.3. CoQ10 and Specific Conditions Associated with Age
The case for beneficial effects of CoQ10 or ubiquinol supplementation is stronger for a number
of aging-related diseases many of which have documented mitochondrial dysfunction or CoQ10
deficiency. Despite this, the majority of studies proving therapeutic effects of CoQ10 supplementation
were carried out in animal models [25].
Early studies were carried out with CoQ10 although often information on the formulation used
is lacking (it is known that ubiquinol can be 3 to 4 times better absorbed than ubiquinone). Also,
the doses used in most of the studies were lower than the doses studied for primary CoQ10 deficiency
(up to 1200 mg/day) and in secondary CoQ10 deficiency studies. The formulation and absorption
will affect studies of treatment efficacy. A colloidal-Q10 formulation has been shown to have a better
enteral absorption and bioavailability in human tissues, and also the vehicle of the active ingredient
can impact the results of trials [123].
3.3.1. Neurodegenerative Disorders
Neurodegenerative diseases involve neuro-inflammation and oxidative stress, with ROS
accumulation and mitochondrial dysfunction [83,124,125].
The data supporting mitochondrial cofactor supplementation in aging and the aging-related
diseases, including Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple
sclerosis, are addressed in focused review articles in this supplement. A systematic review published in
2014 reviewed 16 articles and concluded that there is no available data from randomized controlled trials
(RCTs) to support the use of mitochondrial supplements for Parkinson disease, atypical Parkinsonism,
Huntington disease, and Friedreich ataxia [126].
Previous studies have shown that patients with Lewy’s body disease and amyotrophic lateral
sclerosis have lower CoQ10 plasma levels and Alzheimer disease patients have reduced levels of CoQ10
in the cerebral spinal fluid [127,128].
In Huntington disease, increased levels of cortical lactate were observed, which were normalized
after 2 months of Coenzyme Q10 oral supplementation at a dose of 360 mg/day. In another publication,
after discontinuation of the supplement, the lactate levels rose again [67,124]. This study does provide
evidence for CNS penetration of administered CoQ10 in humans. These and other data lead to
a multicenter RCT with 609 patients, which could not identify a benefit in Functional Capacity Score
and time to death after 60 months of 2400 mg per day of CoQ10 supplementation compared to
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placebo [129]. Thus, currently, there is insufficient evidence to support CoQ10 supplementation as
a treatment to delay neurodegeneration in Huntington disease even in the early stages of the disease.
A similar situation occurred in Parkinson disease. An early study found that patients had decreased
levels of α-tocopherol and CoQ10 in plasma and cerebrospinal fluid with increased levels of lipoprotein
oxidation compared to controls in a 2004 study of 161 subjects. [130]. Mitochondrial complexes I
and II/III were reduced in platelet mitochondria from early Parkinson disease patients [131]. A more
recent study confirmed the association of Parkinson’s disease and CoQ10 deficiency using Functional
Intracellular Assay, when compared to matched controls for age and gender [132]. A phase 2 study in
80 subjects at early or mid-stage Parkinson disease showed a beneficial effect from supplementation
with CoQ10 in progressive doses of 300, 600, 1200 mg/day for 16 months. There was an improvement
in the ADL UPDRS (Activity Of Daily Living Unified Parkinson Disease Rating Scale) and Schwab and
England scales compared to placebo (+11.99), with highest dose (+6.69) having the best effect [133].
This lead to a phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American
sites by the Parkinson Study Group which used doses up to 2400 mg/day of CoQ10 vitamin E in the
dose of 1200 IU/d (to enhance the absorption of the lipophilic coenzyme) however this large study did
not find convincing evidence to support CoQ10 treatment for this disease [7]. A systematic review and
meta-analysis from 2016 could not find sufficient evidence in five selected RCTs to support the use
of ubiquinone (300 mg/day to 2400 mg/day) to decelerate the progression of Parkinson’s disease or
improve symptoms [134].
In aged, cognitively impaired mice, CoQ10 supplementation does improve special learning and
attenuates oxidative damage [135]. In Alzheimer Disease, the Alzheimer’s Disease Cooperative Study
could not identify benefits in the levels of oxidative stress and neurodegeneration biomarkers in CSF
(cerebrospinal fluid) with a dose of 400 mg of CoQ10 3 times/day for 16 weeks for patients [136]. To date,
chronic large-scale trials of CoQ10 have not been carried out in Alzheimer disease.
3.3.2. Cardiovascular Disease
A meta-analysis reviewed randomized controlled trials in healthy adults; two trials reported
reduction in systolic blood pressure, and no evidence for reduction in diastolic blood pressure was
reported. Another trial included in this meta-analysis failed to show an effect of CoQ10 supplementation
on the lipid profile (LDL: low-density lipoprotein cholesterol, HDL: high-density lipoprotein cholesterol,
and triglycerides) [137]. Another meta-analysis from 2016 concluded that there is not enough evidence
to support CoQ10 use to treat hypertension [138]. For dyslipidemia, no relationship was found
between CoQ levels in hyperlipidemic and normolipidemic, older women and no association with
body mass index was found [139]. Statins are well known to reduce CoQ10 levels because of inhibition
of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme is the first step in
the mevalonic acid synthesis pathway, which is necessary for the synthesis of cholesterol but also the
isoprenoid side-chain of CoQ10 [140].
Patients with mitochondrial myopathy do not tolerate statin treatment, often developing exercise
intolerance and myalgia when treated with statins. These symptoms may improve with CoQ10 oral
supplementation [141–143]. Statins were also found related to a reduction in complex III activity.
However, the exact mechanism for the mitochondrial myotoxicity of statins is not well understood and
other factors than CoQ10 can be involved, such as genetic polymorphisms [144].
There is evidence that cardiac function in the elderly may be improved by CoQ10 treatment.
This effect may be related to the documented fall in cardiac CoQ10 levels in the aged heart [114].
A meta-analysis reviewed eight clinical trials and concluded that patients submitted to cardiopulmonary
bypass have a decreased requirement for ionotropic drugs and a reduced chance of ventricular
arrhythmia if receiving CoQ10 supplementation [145].
The best case for CoQ10 supplementation is in cardiovascular disease. It was recently reported
that 12 years after a 4-year double-blind treatment protocol in the elderly co-supplemented with
selenium (200 µg) and CoQ10 (200 mg/day) (ubiquinone in a softgel vehicle of vegetable oils) the treated
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subjects still had a reduced cardiovascular mortality (38.7% in placebo-treated group versus 28.1% in
CoQ-treated group) [146]. The Q-SYMBIO trial enrolled 420 patients and showed that CoQ10 100 mg
3 times daily for 2 years plus standard therapy reduced the risk of cardiovascular events, in this study
measured as cardiovascular mortality (16% in placebo and 9% in the treated group) and hospitalization
for heart failure compared to placebo, and also a positive change in the New York Heart Association
(NYHA) functional classification (26% in placebo and 15% in the treated group) [147]. A recent review
of the use of CoQ10 in heart failure is recommended [39].
3.3.3. Endothelial Dysfunction
Endothelial function may be a risk factor for coronary artery disease and atherosclerosis. CoQ10
together with a Mediterranean diet was shown to improve markers of endothelial function in elderly
patients [148,149].
3.3.4. Renal Disease
Although ubiquinol can improve the endothelial dysfunction associated with the diabetic kidney
disease (systolic blood pressure and urinary albumin) [150], and a trial with CoQ10 supplementation
(1200 mg/day in dialysis patients) identified a reduction in a plasma indicator of oxidative stress
(F2-isoprostane) [151], a meta-analysis failed to prove CoQ10 efficacy in avoiding the progression of
diabetic kidney disease [152].
3.3.5. Inflammation
Many aging-related diseases share a common physiologic pathway of chronic inflammation
leading to oxidative stress, such as cardiovascular diseases, diabetes, cancer, and chronic kidney disease.
A recent meta-analysis reports a reduction in the plasma inflammatory biomarkers, C-reactive
protein, IL-6, and TNF-α, after CoQ10 supplementation (60 to 500 mg/day, formulations described as
CoQ10 or ubiquinol), for 1 week to 4 months in different inflammatory disorders (cardio and cerebral
vascular disease, multiple sclerosis, obesity, renal failure, rheumatoid arthritis, diabetes, and fatty
liver disease). The same review reports that CoQ10 decreases other biomarkers for inflammation
and inflammatory cytokines [30]. Although CoQ10 treatment has been shown to improve markers of
inflammation, a benefit of chronic treatment for the diseases associated with inflammation has not
been demonstrated.
CoQ10 (100 mg/day) supplementation for 2 months decreased the levels of TFN-α in rheumatoid
arthritis patients compared to placebo, [153]. A more recent systematic review and meta-analysis
reported CoQ10 supplementation between 60 to 300 mg/day (no extra information about formulations)
was associated with a slightly drop in C-reactive protein levels and a significant decrease in in IL-6
levels [154].
Down syndrome patients have an abnormal pro-inflammatory profile (increased IL-6 and
TNF-α) [36,37] and reduced CoQ10 levels, and supplementation reduced markers of oxidative stress
and mitochondrial dysfunction [38,155].
3.3.6. Osteoporosis
Animal and human studies have demonstrated that benefits of CoQ10 supplementation have
a beneficial profile for osteoporosis [156–158].
3.3.7. Cancer
There is evidence of the relationship between some cancers and reduced CoQ10 levels in blood,
particularly breast cancer [159], myeloma [160], melanoma [161], and follicular and papillary thyroid
carcinomas [162]. There is also evidence that CoQ10 supplementation modulates phospholipid
hydroperoxide glutathione peroxidase gene expression, free radical production, and can decelerate the
growth of tumor cells in a prostate cancer line (PC3 line) [163].
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4. Conclusions
There is still much to be learned about the pathophysiology of the process of aging. There are
well documented reductions of tissue CoQ10 in senescence. It is not known if low CoQ10 is an effect
of aging, perhaps matching the fall in mitochondrial electron transport function or a contributing
cause to the aging process. There is accumulating evidence that some diseases of aging may benefit
from supplemental ubiquinol or CoQ10 treatment. Studies to date have supported the safety and
the potential of CoQ10 in reducing oxidative stress biomarkers. There remains a lack of adequate
large-scale clinical trials preferably utilizing ubiquinol as the better absorbed form of CoQ10. Despite
the lack of evidence, large numbers of people in the population are taking CoQ10 and other vitamins
and cofactors in the hope that these agents will slow senescence and expand longevity.
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